Sinovac Biotech Ltd (SVA)

Etorro trading 970x250

About Sinovac Biotech Ltd

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People’s Republic of China. The company’s product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People’s Republic of China. Address: No.39, SHANGDI West Road, Beijing, China, 100085

Sinovac Biotech Ltd News and around…

Latest news about Sinovac Biotech Ltd (SVA) common stock and company :

Evotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes
17 May, 2022 FinancialContent

HAMBURG, GERMANY, and LONDON, ON / ACCESSWIRE / May 17, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Sernova Corp. (TSX-V: SVA; OTCQB: SEOVF; FSE: PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics today announced a partnership in the field of diabetes. Both Companies will leverage their respective strengths to develop an implantable iPSC-based beta cell replacement therapy for the treatment of insulin-dependent diabetes, including type 1 and 2.

SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
06 May, 2022 FinancialContent

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, is aware that the Company has been identified by the United States Securities and Exchange Commission (“SEC”) under the Holding Foreign Companies Accountable Act of the United States (the “HFCAA”) on May 4, 2022. Similar to other companies that have also been identified, SINOVAC notes such identification resulted from the Company’s filing of its annual report on Form 20-F for the fiscal year ended December 31, 2021. SINOVAC has previously disclosed that its auditor, the independent registered public accounting firm that issued the audit report included in its annual report filed with the SEC, is in a jurisdiction currently listed as not being able to be fully inspected by the PCAOB, and thus the identification was expected. SINOVAC will continue to closely monitor developments and explore options in relation to the HFCAA.

HFCAA News: 128 Chinese Stocks the SEC Could Delist
05 May, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The SEC has released a massive list of Chinese stocks that could face delisting on Holding Foreign Companies Accountable Act news. The post HFCAA News: 128 Chinese Stocks the SEC Could Delist appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
29 Apr, 2022 FinancialContent

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. The Company also reported its unaudited financial for the second half and full year ended December 31, 2021.

Are These 2 Rivals Beating Pfizer and Moderna?
28 Mar, 2022 FinancialContent

They're winning when it comes to orders.

Sinovac Amends Shareholder Rights Plan
22 Feb, 2022 FinancialContent

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2022 to February 22, 2023.

New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report
26 Jan, 2022 FinancialContent

Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education ...

Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
24 Jan, 2022 FinancialContent

A third booster dose of a COVID-19 vaccine from eitherAstraZeneca Plc(NASDAQ: AZN),Pfizer Inc(NYSE: PFE) ...

Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A
20 Jan, 2022 FinancialContent
Nightmare Vaccine Logistics Are Prolonging the Global Pandemic
19 Jan, 2022 Yahoo! Finance

(Bloomberg) -- After losing her son to Covid-19 last year, 79-year-old Tomasa Valdez was desperate to get vaccinated. But on the remote Philippine island of San Salvador, where she lives, there were no shots to be had. Most Read from BloombergJeremy Grantham Doubles Down on Crash Call, Says Selloff Has StartedTech Leads Late-Day Slide in Stocks; Bitcoin Sinks: Markets WrapCrypto Selloff Pushes Bitcoin to a Six-Month Low of $38,000American Airlines Sues The Points Guy Over Its Rewards Management

Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron: Reuters
03 Jan, 2022 FinancialContent

China-basedSinovac Biotech Ltd's(NASDAQ: SVA) two-dose COVID-19 vaccine followed by a boosterPfizer ...

SINOVAC Reports Unaudited First Half of 2021 Financial Results
30 Dec, 2021 FinancialContent

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2021.

Antigua Court of Appeal Rules in Favor of SINOVAC, Upholds 2018 Judgment
09 Dec, 2021 FinancialContent

SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today provided an update for shareholders with regard to the exchange (the “Exchange”) of preferred share purchase rights (the “Rights”) for the Company’s Common Shares and Series B Convertible Preferred Shares (the “Exchange Shares”), originally announced via press release on February 22, 2019. At that time, Sinovac’s Board determined that certain collaborating shareholders had become acquiring persons, thereby triggering the Company’s Rights Agreement. As a result, valid preferred share purchase rights held by all non-collaborating shareholders were exchanged for common and preferred shares, per the terms of the Rights Agreement.

SINOVAC Beijing Settled Litigation of Its Business License and Seals
03 Dec, 2021 FinancialContent

SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced the Company’s subsidiary SINOVAC Biotech Co., Ltd (“SINOVAC Beijing”) settled the litigation with Mr. Aihua Pan concerning its business license and seals.

Hong Kong authorises Sinovac vaccine for children aged 3-17
20 Nov, 2021 Yahoo! Finance

Hong Kong has approved lowering the age limit for the COVID-19 vaccine from China's Sinovac Biotech to three years old, down from 18 years of age, as it pursues a broader campaign to incentivise its 7.5 million residents to get vaccinated. "Adolescents aged 12 to 17 will be accorded priority to receive the CoronaVac vaccine, with a view to extending to children of a younger age group at a later stage," Hong Kong's Secretary for Food and Health (SFH) Sophia Chan said in a statement published on Saturday. According to the statement, the SFH considered that the benefits of approving the extension of the age eligibility to cover those aged three to 17 "outweigh the risks".

Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
09 Nov, 2021 Yahoo! Finance

BEIJING, November 09, 2021--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced new preliminary data on its inactivated COVID-19 vaccine CoronaVac®. The results from statistics analysis under blind status indicated that CoronaVac® is safe for healthy people of different races in the pediatric and adolescent population ranging from 3 to 17 years of age.

Zimbabwe approves Sinovac shots for older teenagers
01 Nov, 2021 Yahoo! Finance

Zimbabwe's health ministry has approved the use of China's Sinovac Biotech COVID-19 vaccine for 16- and 17-year-olds, it said on Monday, adding that the country aimed to achieve herd immunity by the end of December. "All the provinces, secondary schools, colleges, universities and vaccination centres are hereby required to commence the vaccination campaign of this age group with immediate effect," the minister said. A growing number of countries have approved https://reut.rs/3BzSQZb, or are considering approving, COVID-19 vaccinations for children and adolescents.

China Vaccine Diplomacy Wavers as Nations Seek Western Shots
30 Sep, 2021 Yahoo! Finance

(Bloomberg) -- In the early days of the Covid-19 vaccine rollout, Chinese shots saved countless lives. They kick-started inoculation programs across Asia, Latin America and the Middle East, while richer countries hoarded scarce mRNA shots from Pfizer Inc. and Moderna Inc.Most Read from BloombergChristmas at Risk as Supply Chain ‘Disaster’ Only Gets WorseReshaped by Crisis, an ‘Anti-Biennial’ Reimagines ChicagoThis Is What Europe’s Green Future Looks LikeWhy the Gaza Strip May Be the City of the

Rebuffed by Bolsonaro, Brazil medical institute to sell vaccines abroad
29 Sep, 2021 Yahoo! Finance

Brazil's Butantan biomedical institute is in talks to sell a locally manufactured COVID-19 vaccine developed by China's Sinovac to other countries in South America and Africa, as the federal government has not ordered more of the shots. Butantan Director Dimas Covas said on Wednesday that the institute also has contracts to supply the vaccine directly to Brazilian states. Butantan is currently producing the shot developed by Sinovac Biotech Ltd in the Sao Paulo state using inputs imported from China, but it aims to complete a factory for 100% local production by early next year.

UPDATE 2-Sinovac in talks about setting up South Africa vaccine production
10 Sep, 2021 Yahoo! Finance

China's Sinovac Biotech is in talks about setting up a vaccine production facility in South Africa to supply the African continent with shots against a range of diseases, the chief executive of its local partner said on Friday. Numolux Group CEO Hilton Klein made the comments at the launch of the South African leg of a global Phase III trial of Sinovac's COVID-19 vaccine in children and adolescents.

Sinovac in talks about setting up S.Africa vaccine production, partner says
10 Sep, 2021 Yahoo! Finance

China's Sinovac Biotech is in talks about setting up a vaccine production facility in South Africa with its local partner, the chief executive of the partner said on Friday. Numolux Group CEO Hilton Klein made the comments at the launch of the South African leg of a global Phase III trial of Sinovac's COVID-19 vaccine in children and adolescents. "This clinical trial is a precursor to the establishment of a South African vaccine manufacturing facility partnered by Sinovac and Numolux Group that will cover the entire spectrum of vaccinations beyond just the COVID-19 response," Klein told a news conference.

UPDATE 1-Sinovac to trial COVID-19 vaccine in South African children as part of global study
09 Sep, 2021 Yahoo! Finance

China's Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Sinovac and local partner Numolux Group said on Thursday. The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement. The global trial will enrol 14,000 participants across Chile, the Philippines, Malaysia and Kenya, including 2,000 in South Africa, they said.

Sinovac to trial COVID-19 vaccine in South African children in global study
09 Sep, 2021 Yahoo! Finance

China's Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Sinovac and local partner Numolux Group said on Thursday. The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement.

UPDATE 1-European regulator says more data needed on Sputnik, Sinovac vaccines
09 Sep, 2021 Yahoo! Finance

The European Union's drugs regulator said it was awaiting more data on Russia's Sputnik V and a rival COVID-19 vaccine by China's Sinovac Biotech before it can progress on its rolling reviews of the two shots. "For these vaccines the discussion with the companies has been quite constructive but it looks like there are more data that need to be submitted to us before we can progress with the different rolling reviews," the European Medicines Agency's (EMA) head vaccines strategy, Marco Cavaleri, told a press briefing. He added EMA would continue to review data on German biotech firm CureVac's shot over the next few weeks before a conclusion can be drawn.

New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant
09 Sep, 2021 Yahoo! Finance

BEIJING, September 09, 2021--SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced a paper, titled "A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2," is available on medRxiv. The findings suggest a third dose of CoronaVac® can induce a better neutralization breadth to variants of concern ("VOCs"), including the Delta variant, a rapid immunolog

Brazilian regulator still unsatisfied with safety of 12 mln Coronavac doses
08 Sep, 2021 Yahoo! Finance

Brazil's federal health regulator said on Wednesday that documents provided by a Sao Paulo biomedical center attesting to the safety of over 12 million doses of the Coronavac COVID-19 vaccine were insufficient to ensure their safety. Last week, the regulator, known as Anvisa, suspended the use of millions doses of the vaccine developed by China's Sinovac Biotech Ltd, as they were produced in a plant that had not been authorized by the authority. Anvisa said in a statement at the time that it was alerted by the Butantan biomedical institute, which has partnered with Sinovac to locally fill and finish the vaccines, that roughly 12.1 million doses sent to Brazil had been made at the plant.

SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents
08 Sep, 2021 Yahoo! Finance

BEIJING, September 08, 2021--SINOVAC Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. ("SINOVAC"), a subsidiary of the Company, received approval from the Public Health Institute of Chile ("ISP") for emergency use for children and adolescents aged between 6 and 17.

Sernova to Present Corporate Update at Canaccord Genuity's 41st Annual Growth Conference
09 Aug, 2021 FinancialContent
Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
05 Jul, 2021 FinancialContent
Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs
30 Jun, 2021 FinancialContent

Sinovac Biotech Ltd (SVA) is a NASDAQ Common Stock listed in , ,

970x250